A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Maimonides Medical Center, Brooklyn, New York, United States
Ole Broch, Kiel, Schleswig-Holstein, Germany
Hospital Henri Duffaut, Avignon, Paca, France
Sahlgrenska University Hospital, Gothenburg, Sweden
Trevor Mann Baby Unit, Brighton, Sussex, United Kingdom
Francesco Pugliese, Rome, Italy
Kartal Kosuyolu High Speciality Training and Research Hospital, Istanbul, Turkey
Leviev Heart Center, Chaim Sheba Medical Center, Ramat-Gan, Israel
La Paz University Hospital, Madrid, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.